443 related articles for article (PubMed ID: 11932286)
1. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
Carrel AL; Myers SE; Whitman BY; Allen DB
J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
[TBL] [Abstract][Full Text] [Related]
2. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
Carrel AL; Myers SE; Whitman BY; Allen DB
J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
[TBL] [Abstract][Full Text] [Related]
3. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
Myers SE; Carrel AL; Whitman BY; Allen DB
J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study.
Carrel AL; Myers SE; Whitman BY; Allen DB
J Pediatr; 1999 Feb; 134(2):215-21. PubMed ID: 9931532
[TBL] [Abstract][Full Text] [Related]
5. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
Carrel AL; Allen DB
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1445-51. PubMed ID: 11837498
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
[TBL] [Abstract][Full Text] [Related]
8. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
Höybye C
Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
Allen DB; Carrel AL
J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1297-306. PubMed ID: 15506076
[TBL] [Abstract][Full Text] [Related]
11. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
[TBL] [Abstract][Full Text] [Related]
12. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
13. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome.
Höybye C
Acta Paediatr; 2007 Mar; 96(3):410-3. PubMed ID: 17407467
[TBL] [Abstract][Full Text] [Related]
14. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits.
Myers SE; Whitman BY; Carrel AL; Moerchen V; Bekx MT; Allen DB
Am J Med Genet A; 2007 Mar; 143A(5):443-8. PubMed ID: 17103437
[TBL] [Abstract][Full Text] [Related]
15. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome.
Lafortuna CL; Minocci A; Capodaglio P; Gondoni LA; Sartorio A; Vismara L; Rizzo G; Grugni G
J Clin Endocrinol Metab; 2014 May; 99(5):1816-24. PubMed ID: 24471571
[TBL] [Abstract][Full Text] [Related]
16. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome.
L'Allemand D; Eiholzer U; Schlumpf M; Torresani T; Girard J
Horm Res; 2003; 59(5):239-48. PubMed ID: 12714788
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
Höybye C; Hilding A; Jacobsson H; Thorén M
Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
